Document:

exv10w1

 

	 	 	 
	

	 	LifeScan, Inc. 1000 Gibraltar Drive, Milpitas, CA
95035-6312

 Tel: 408-263-9789 Fax: 408.946.6070
www.LifeScan.com

December 7, 2005

Andrew Denver

Chairman

Universal Biosensors Inc

27, Woodviile Ave

Wahroonga NSW 2076

Australia

Dear Andrew,

I am writing to you today to propose amending our current License Agreement.

This amendment will be effective as of the date of this letter and amends the License Agreement
(“Agreement”) entered into the 1st day of April, 2002 by and between Universal
Biosensors, Inc., a Delaware corporation having a principal place of business at 2711 Centerville
Road, Suite 400, Wilmington, Delaware 19808 (“Universal Biosensors”) and LifeScan Inc., a
California corporation having its principal place of business at 1000 Gibraltar Drive, Milpitas,
California 95035 (“LifeScan”). LifeScan and Universal Biosensors are sometimes collectively
referred to herein individually as a “Party” or collectively as the “Parties.”

In consideration for the covenants and undertakings set forth herein and in the
Agreement, the Parties hereby agree;

Section 1.6 is hereby deleted in its entirety and replaced by the following Section:

     1.6 “LIFESCAN’s Field” means diabetes, including, without limitation:

	 	(a)	 	measurement of analytes for purposes of diagnosing,
managing, monitoring, prognosticating, treating, or curing diabetes; and
	 
	 	(b)	 	the measurement of glucose in humans for any other
purpose, including, without limitation, tight glycemic control

Page 1 of 2 

 

The Parties agree that all other provisions in the Agreement remain.

In witness whereof, LifeScan and Universal Biosensors have caused these present to be signed.

AGREED AND ACCEPTED TO:

	 	 	 	 	 	 	 	 	 
	UNIVERSAL BIOSENSORS INC	 	 	 	LIFESCAN, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Andrew Denver
	 	 	 	By:
	 	/s/ Eric P. Milledge
	 

	 	 
	 	 	 	 	 	 
	Name: Andrew Denver	 	 	 	Name: Eric P. Milledge
	Title: Chairman	 	 	 	Title: Company Group Chairman
	Date: Jan 9 2006	 	 	 	Date: 01/04/06

Page 2 of 2 

 

Exhibit 10.1

LICENSE AGREEMENT

     THIS AGREEMENT, is by and between LifeScan, Inc., a California corporation having its
principal place of business at 1000 Gibraltar Drive, Milpitas, California 95035 (“LIFESCAN”), and
Universal Biosensors Inc., a Delaware corporation having its principal place of business at 2711
Centerville Road, Suite 400, Wilmington, Delaware 19808 (“UNIVERSAL BIOSENSORS”).

     WHEREAS, LIFESCAN has acquired from USF Filtration and Separations Group Inc. (“FSG”) all
right, title, and interest in and to certain know-how, patents and patent applications relating to
electrochemical sensors;

     WHEREAS, UNIVERSAL BIOSENSORS desires to obtain a license in and to this know-how and these
patents and patent applications and LIFESCAN desires to grant the license to UNIVERSAL BIOSENSORS.

     NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, the
parties agree to the following:

	1.	 	DEFINITIONS.

	 	1.1	 	“Affiliate” means any entity that directly or indirectly controls, is
controlled by, or is under common control with a party to the Agreement. “Control”
shall mean the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of the entity, whether through the ownership
of voting securities, by contract or otherwise.
	 
	 	1.2	 	“Effective Date” means April 1, 2002.
	 
	 	1.3	 	“Field” means a field-of-use.
	 
	 	1.4	 	“Licensed Fields” means all Fields outside of LIFESCAN’s Field.
	 
	 	1.5	 	“LIFESCAN Acquired Know-How” means all know-how, data, and information acquired
from FSG by LIFESCAN and related to the LIFESCAN Patents.
	 
	 	1.6	 	“LIFESCAN’s Field” means:

     a.) measurement of analytes for purposes of diagnosing, managing, monitoring,
prognosticating, treating, or curing diabetes:

     b.) measurement of blood coagulation; and

 

 

     c.) measurement for purposes of diagnosing, managing, monitoring, prognosticating,
treating, or curing blood coagulopathies excluding the measurement of total
hemoglobin.

	 	1.7	 	“LIFESCAN Acquired Patents” means those applications and patents acquired by
LIFESCAN from FSG and identified on Exhibit A attached hereto and made a part hereof,
as well as any patents issuing therefrom, foreign counterparts, divisions,
continuations, renewals, reissues, re-examinations, patent extensions, and
substitutions thereof.
	 
	 	1.8	 	“Product” means an article within the Licensed Fields that either falls within
the scope of a Valid Claim of one of the LIFESCAN Acquired Patents or embodies LIFESCAN
Acquired Know-How.
	 
	 	1.9	 	“Term” means the period beginning on the Effective Date and ending at the end
of the term of the last to expire of the LIFESCAN Acquired Patents unless terminated
earlier pursuant to Section 5.
	 
	 	1.10	 	“Valid Claim“ means a claim of an issued, unexpired patent that has not been
held invalid by a court of competent jurisdiction or held unpatentable in a
re-examination procedure in the United States Patent and Trademark Office.

	2.	 	LICENSE.

	 	2.1	 	a.) Subject to the provisions of paragraph 2.2 and Section 3, as of the
Effective Date and for the Term, LIFESCAN hereby grants to UNIVERSAL BIOSENSORS a
worldwide, royalty-free, exclusive license, with the right to sublicense, to make, have
made, use, sell under and exploit in any way the LIFESCAN Acquired Patents and the
LIFESCAN Acquired Know-How in the Licensed Fields.
	 
	 	 	 	b.) In order to exercise UNIVERSAL BIOSENSORS’ rights to sublicense any or all of
the rights licensed under paragraph 2.1a.), UNIVERSAL BIOSENSORS shall provide that
each sublicense contains the terms and conditions set forth in Section 3 and
paragraph 4.6 of this Agreement
	 
	 	2.2	 	The license granted in paragraph 2.1a.) is subject to a reserved non-exclusive
license in LIFESCAN and its Affiliates to make, have made, use, sell under and exploit
in any way the LIFESCAN Acquired Patents and LIFESCAN Acquired Know-How in the Licensed
Fields .

2

 

	 	2.3	 	In consideration of the license granted under paragraph 2.1a.), UNIVERSAL
BIOSENSORS hereby grants to LIFESCAN a worldwide, royalty-free, irrevocable,
non-exclusive license to make, have made, use, and sell under and exploit in any way in
LIFESCAN’s Field any and all intellectual property resulting from UNIVERSAL BIOSENSORS’
improvements, modifications, or adaptations whether or not patentable (collectively,
“Improvements”) in respect of the LIFESCAN Acquired Patents, LIFESCAN Acquired
Know-How, or both.
	 
	 	 	 	a.) All right, title and interest in and to the Improvements shall be in
UNIVERSAL BIOSENSORS and UNIVERSAL BIOSENSORS at its sole discretion
may, if registerable, register any of the Improvements in such
territories (if any) that UNIVERSAL chooses.
	 
	 	 	 	b.) UNIVERSAL BIOSENSORS shall, at LIFESCAN’s expense, grant
registerable user or license agreements in respect of any registered
intellectual property in any Improvements that LIFESCAN determines is
required in any particular territory to make the license in this
paragraph 2.1 effective.
	 
	 	 	 	c.) Registered user or license agreements under paragraph 2.2 b.) shall
be consistent with this paragraph 2.2, but otherwise shall be in usual
or common form.

	3.	 	RECAPTURE RIGHTS.

	 	3.1	 	In order for UNIVERSAL BIOSENSORS to maintain the exclusive license granted in
paragraph 2.1a.), UNIVERSAL BIOSENSORS shall use its best efforts to use and exploit
the LIFESCAN Acquired Patents and LIFESCAN Acquired Know-How in the Licensed Fields;
provided, however that
UNIVERSAL BIOSENSORS retains the discretion to determine the means and manner of its
exploitation of LIFESCAN Acquired Patents and LIFESCAN Acquired Know-How. For
purposes of this Section 3, “exploit” or “exploitation” means:

	 	a.)	 	using in research and development activities:
	 
	 	b.)	 	using in developing, making, selling, and distributing Products;
	 
	 	c.)	 	granting sublicenses in any Field within the Licensed Fields; and.
	 
	 	d.)	 	developing, in conjunction with a.), b.) or c.), new patent
applications or other intellectual property that derives from or, is a
development of, any of the LIFESCAN Acquired Patents and LIFESCAN Acquired
Know-How in the Licensed Fields.

3

 

	 	3.2	 	During the Term, UNIVERSAL BIOSENSORS shall provide to LIFESCAN periodic,
written, summary reports on UNIVERSAL BIOSENSORS’ exploitation plans and any
Improvements to which paragraph 2.3 applies, which reports shall be provided at
least one (1) time per calendar year. LIFESCAN shall keep confidential any
exploitation plans disclosed to it in under this paragraph 3.2.
	 
	 	3.3	 	In the event that LIFESCAN is approached by a third party that desires a
license in a Field within the Licensed Fields in any or all of the LIFESCAN Acquired
Patents or LIFESCAN Acquired Know-How, LIFESCAN shall refer the third party to
UNIVERSAL BIOSENSORS by identifying the third party, identifying a contact for the
third party, and providing UNIVERSAL BIOSENSORS copies of any correspondence received
by LIFESCAN from the third party (collectively, a “Referral”). UNIVERSAL BIOSENSORS
shall acknowledge in writing to LIFESCAN receipt of the Referral within thirty (30)
days of such receipt.
	 
	 	3.4	 	If UNIVERSAL BIOSENSORS receives a Referral pursuant to paragraph 3.3,
UNIVERSAL BIOSENSORS shall enter into good faith negotiations for grant of a license
to the third party unless UNIVERSAL BIOSENSORS:

	 	a.)	 	is engaged in exploitation of the LIFESCAN Acquired Patents or
LIFESCAN Acquired Know-How, as applicable, in the Field that is the subject of
the Referral; or
	 
	 	b.)	 	provides to LIFESCAN evidence that reasonably demonstrates to
LIFESCAN that UNIVERSAL BIOSENSORS has bona fide plans to
commence exploitation of the LIFESCAN Acquired Patent or LIFESCAN Acquired
Know-How, as applicable, in the Field within twelve (12) months of the date of
UNIVERSAL BIOSENSORS’ acknowledgment of the Referral.

	 	3.5	 	If UNIVERSALBIOSENSORS fails to enter into negotiations under paragraph 3.4
within three (3) months of the date of UNIVERSAL BIOSENSORS’ acknowledgment of the
Referral, LIFESCAN shall have the right to convert the license granted under paragraph
2.1a.) to a non-exclusive license with respect to the Field and LIFESCAN Acquired
Patent or LIFESCAN Acquired Know-How that is the subject of the Referral;

	4.	 	Patent Prosecution and Maintenance; Patent Marking.

4

 

	 	4.1	 	a.) LIFESCAN shall accept liaison and financial responsibility for prosecution
by a patent attorney, in independent practice nominated by LIFESCAN and approved by
UNIVERSAL BIOSENSORS, of the application or applications within the LIFESCAN Acquired
Patents directed to inventions within the Licensed Fields to allowance or to the point
of necessary appeal from a final rejection by an Examiner of the USPTO, and those
jurisdictions listed on Exhibit B attached hereto and made apart hereof and any other
jurisdiction mutually agreed upon by the parties.

	 	b.)	 	Except as may be later separately agreed upon by the parties in
writing, LIFESCAN does not accept responsibility for:
	 
	 	 	 	i.) filing or prosecution of any appeal from a final rejection by an
Examiner of the USPTO, or any other jurisdiction, of any of the patent
applications; or
	 
	 	 	 	ii.) the conduct of any interference in which an application or patent
arising from an application may become involved.

	 	4.2	 	LIFESCAN will furnish UNIVERSAL BIOSENSORS copies of all office actions and
LIFESCAN’s proposed responses thereto at least thirty (30) days prior to the earliest
date set by the USPTO or corresponding foreign office for submission of the response
and UNIVERSAL BIOSENSORS shall have the right to review and comment on LIFESCAN’s
proposed response to such action.
	 
	 	4.3	 	In the event that LIFESCAN elects not to proceed with the prosecution of an
application under subparagraph 4.1 a.), LIFESCAN shall notify UNIVERSAL BIOSENSORS of
such decision and UNIVERSAL BIOSENSORS shall have the right at any time thereafter to
assume and continue at its own expense the prosecution of the application. Upon
receipt by UNIVERSAL BIOSENSORS of such notice from LIFESCAN, LIFESCAN:

	 	a.)	 	shall be relieved of all further financial and other
responsibility in respect to the application;
	 
	 	b.)	 	 shall have no further rights thereto in all jurisdictions for
which UNIVERSAL BIOSENSORS assumes financial responsibility for the
prosecution;
	 
	 	c.)	 	 shall enter into such assignments or other reasonably necessary
documents in respect thereto in all jurisdictions for which UNIVERSAL
BIOSENSORS assumes financial responsibility so as to properly vest

5

 

	 	 	 	ownership and the right to prosecute the application in UNIVERSAL BIOSENSORS
or its nominee; and
	 
	 	d.)	 	shall provide to UNIVERSAL BIOSENSORS the file histories of the
application in LIFESCAN’s possession.

	 	4.4	 	Upon issuance of any patents resulting from the applications prosecuted
pursuant to paragraph 4.1, LIFESCAN will accept responsibility for payment of
maintenance fees for all jurisdictions mutually agreed upon by the parties. However,
LIFESCAN shall have the right to discontinue the payment of any or all maintenance fees
in any or all countries. In the event LIFESCAN discontinues such maintenance payments,
LIFESCAN shall notify UNIVERSAL BIOSENSORS of such decision and UNIVERSAL BIOSENSORS
may, at its option, maintain the patent solely at its own expense. Upon receipt by
UNIVERSAL BIOSENSORS of such notice from LIFESCAN, LIFESCAN:

	 	a.)	 	shall be relieved of all further financial and other
responsibility in respect to the patent at issue;
	 
	 	b.)	 	shall have no further rights thereto in all jurisdictions for which
UNIVERSAL BIOSENSORS has assumed the maintenance payments.
	 
	 	c.)	 	shall enter into such assignments or other reasonably necessary
documents in respect thereto in all jurisdictions for which UNIVERSAL
BIOSENSORS assumes financial responsibility so as to properly vest ownership
and the right to maintain the patent in UNIVERSAL BIOSENSORS or its nominee;
and
	 
	 	d.)	 	shall provide to UNIVERSAL BIOSENSORS the file histories of the
patent in LIFESCAN’s possession.

	 	4.5	 	a.) In the event that UNIVERSAL BIOSENSORS grants a sublicense in the LIFESCAN
Acquired Patents and receives a lump sum payment, actual or minimum royalties payment,
or both ( a “Payment”) from the sublicensee, UNIVERSAL BIOSENSORS agrees to pay fifty
percent (50 %) of such Payment (when received from time to time) to LIFESCAN in
reimbursement of LIFESCAN’s payment of the prosecution and maintenance fees under this
Section 4, such payment to LIFESCAN

6

 

	 	 	 	to cease at the end of the term of the LIFESCAN Acquired Patents that are the
subject of the Payment from the sublicensee.

	 	B.)	 	LIFESCAN acknowledges to UNIVERSAL BIOSENSORS that, apart from
the rights to Payments under this paragraph 4.5, LIFESCAN is not entitled to
receive any other amount by way of royalty or similar payment in respect of
the license granted herein.

	 	4.6	 	UNIVERSAL BIOSENSORS agrees to place in a conspicuous location on Products sold
to third parties a patent notice, in accordance with 35 U.S.C. §287, and any
corresponding provision of the laws of a jurisdiction other than the United States in
which a Product is being sold, identifying the relevant LIFESCAN Patents, if any.

	5.	 	TERMINATION.

	 	5.1	 	This Agreement shall extend until the end of the Term unless terminated earlier
in accordance with this Section 5.
	 
	 	5.2	 	This Agreement may be terminated by LIFESCAN in the event that UNIVERSAL
BIOSENSORS fails to exploit the LIFESCAN Acquired Patents and LIFESCAN Acquired
Know-How. For purposes of this paragraph 5.2:

	 	a.)	 	exploit has the same meaning as in paragraph 3.1; and
	 
	 	b.)	 	if LIFESCAN wishes to terminate the Agreement pursuant to this
paragraph 5.2, LIFESCAN shall first provide UNIVERSAL BIOSENSORS with ninety
(90) days written notice of its intent to so terminate and, if at the
expiration of the ninety (90) days, UNIVERSAL BIOSENSORS has not provided
evidence to LIFESCAN that UNIVERSAL BIOSENSORS is exploiting the LIFESCAN
Acquired Patents and the LIFESCAN Acquired Know-How, this Agreement shall
terminate on the 91st day.

	 	5.3	 	This Agreement may be terminated by LIFESCAN in the event that
UNIVERSAL BIOSENSORS is liquidated or is wound up or is in persistent and
material breach of its obligations under this Agreement. LIFESCAN shall first
provide UNIVERSAL BIOSENSORS with ninety (90) days written notice of its intent
to so terminate and, if at the expiration of the ninety (90) days, UNIVERSAL
BIOSENSORS has not rectified the breach, this Agreement shall terminate on the
91st day.

	6.	 	ENFORCEMENT OF PATENTS.

7

 

	 	6.2	 	In the event that UNIVERSAL BIOSENSORS shall bring to LIFESCAN’s attention in
writing any unlicensed infringement, within one of the Licensed Fields, of a LIFESCAN
Acquired Patent and LIFESCAN does not, within six (6) months of receipt of such
writing:

	 	a.)	 	secure cessation of the infringement;

	 
	 	b.)	 	
 enter suit against the infringer; or
	 
	 	c.)	 	engage, along with UNIVERSAL BIOSENSORS, in bona
fide negotiations for the acceptance by the infringer of a sublicense
under the patents,

UNIVERSAL BIOSENSORS shall thereafter have the right to sue for the infringement at its own expense
and to collect for its own use all damages, profits, and awards, of whatever nature.

	 	6.2	 	Nothing in this Agreement shall be construed as an obligation on LIFESCAN’s
part to enforce or defend the LIFESCAN Acquired Patents.

	7.	 	WARRANTIES

	 	7.1	 	Nothing in this Agreement shall be construed as a warranty or representation of
the validity, enforceability, or scope of the LIFESCAN Acquired Patents.
	 
	 	7.2	 	Nothing in this Agreement shall be construed as a warranty or representation
that a Product made, used, or sold under the license granted herein is or will be free
from infringement of the intellectual property of third parties. LIFESCAN shall not be
responsible for any award of damages arising out of charges that UNIVERSAL BIOSENSORS,
alone or in combination with other entities or persons, infringed or infringes any
claim of any third party patent by making, having made, using, selling or otherwise
distributing Products.

LIFESCAN MAKES NO WARRANTIES OF ANY NATURE WITH RESPECT TO THE LIFESCAN PATENTS AND LIFESCAN
KNOW-HOW INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR PARTCIULAR
PURPOSE, OR OTHERWISE.

	8.	 	NOTICES

     All notices, reports, requests, or statements provided for in this Agreement shall be given in
writing and may be served either by personal delivery or by depositing the same, postage prepaid,
in the United States first class, certified, or registered mails (date of deposit will be
considered date of delivery) addressed to the parties respectively at the following addresses:

8

 

	 	a.	 	In the case of UNIVERSAL BIOSENSORS:

Beth Hughes

Venable Attorneys at Law

8010 Towers Crescent Drive

Suite 300

Vienna, Virginia 22182

USA

With a copy to:

Mr. Denis Hanley

Fax: 61 2 4365 5872

	b.	 	In the case of LIFESCAN:

LifeScan, Inc.

1000 Gibraltar Drive

Milpitas, California 95035

Attn: President

Fax: (408) 956-4701

With a copy to:

Chief Patent Counsel

Johnson & Johnson

One Johnson & Johnson Plaza

New Brunswick, New Jersey 08933 U.S.A.

Fax: 732-524-5008

	9.	 	ARBITRATION

     Any controversy or claim arising out of or relating to this Agreement or the validity,
inducement, or breach thereof, shall be settled by arbitration before a single arbitrator in
accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”)
then pertaining (available at www.adr.org), except where those rules conflict with this provision,
in which case this provision controls. Any court with jurisdiction shall enforce this clause and
enter judgment on any award. The arbitrator shall be an attorney who has at least fifteen (15)
years of experience with a law firm or corporate law department of over twenty-five (25) lawyers or
who was a judge of a court of general jurisdiction. He shall be selected within ten days of
commencement of the arbitration from the AAA’s National Roster of Arbitrators pursuant to agreement
or through selection procedures administered by the AAA. The arbitration shall be held in San
Francisco, California and in rendering the award the arbitrator must apply

9

 

the substantive law of New York (except where that law conflicts with this clause), except that the
interpretation and enforcement of this arbitration provision shall be governed by the Federal
Arbitration Act. Within forty-five (45) days of initiation of arbitration, the parties shall reach
agreement upon and thereafter follow procedures assuring that the arbitration will be concluded and
the award rendered within no more than eight months from selection of the arbitrator. Failing such
agreement, the AAA will design and the parties will follow procedures that meet such a time
schedule. Each party has the right before or, if the arbitrator cannot hear the matter within an
acceptable period, during the arbitration to seek and obtain from the appropriate court provisional
remedies such as attachment, preliminary injunction, replevin, etc., to avoid irreparable harm,
maintain the status quo or preserve the subject matter of the arbitration. THE ARBITRATOR SHALL
NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, AND EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT TO SEEK SUCH DAMAGES. NO PARTY MAY SEEK OR OBTAIN PREJUDGMENT
INTEREST OR ATTORNEYS’ FEES OR COSTS.

	10.	 	GENERAL PROVISIONS.

	 	10.1	 	This Agreement, or any of its rights and obligations, shall not be assigned or
transferred in whole or in part by either party without the prior written consent of
the other party.

	 	a.)	 	Any attempted assignment or transfer of such rights or
obligations without consent shall be void.
	 
	 	b.)	 	A party shall not unreasonably withhold its consent to an
assignment or transfer as part of the sale of the whole or part of the business
of the assignor or transferor and the assignee or transferee is of reasonable
financial standing.

	 	10.2	 	This Agreement shall be binding and inure to the benefit of the respective
parties and their successors and assigns.
	 
	 	10.3	 	The waiver of either party, whether express or implied, of any provision of
this Agreement, or of any breach or default of either party, shall not be construed to
be a continuing waiver of such provision, or any succeeding breach or default or of a
waiver of any other provision of this Agreement.
	 
	 	10.4	 	The interpretation, validity, and performance of this Agreement shall be
governed by the laws of the State of New York, except for such laws directing
application of the laws of another jurisdiction.
	 
	 	10.5	 	Each party shall comply with all applicable United States and foreign
governmental laws and regulations including, without limitation, any such laws directed
to importation and exportation.

10

 

AGREED AND ACCEPTED TO:

	 	 	 	 	 	 	 	 	 
	UNIVERSAL BIOSENSORS INC.	 	 	 	LIFESCAN, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Denis Hanley	 	 	 	By:	 	/s/ Eric P. Milledge
	 

	 	 
	 	 	 	 	 	 
	Name:

	 	Denis Hanley	 	 	 	Name:	 	Eric P. Milledge
	Title:

	 	Director	 	 	 	Title:	 	Company Group Chairman
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	April 9, 2002	 	 	 	Date:	 	April 4, 2002
	 

	 	 
	 	 	 	 	 	 

11

 

EXHIBIT A

LIFESCAN Patents

12

 

EXHIBIT A

Sensor Patents Granted

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	USF Reference	 	Title	 	Owner	 	Country	 	Patent Number	 	Issue Date	 	Issue Date
	AU-C089
	 	Analytic Cell	 	FSG	 	AU	 	719581	 	11-Sep-1997	 	11-Sep-1997
	AU-C089
	 	Analytic Cell	 	FSG	 	US	 	6193865	 	27-Feb-2001	 	15-Mar-1999
	AU-C056
	 	Electrochemical Cell	 	FSG	 	AU	 	712939	 	19-Jun-1996	 	19-Jun-1996
	AU-C056
	 	Electrochemical Cell	 	FSG	 	SG	 	53339	 	17-Aug-1999	 	19-Jun-1996
	AU-C056
	 	Electrochemical Cell	 	FSG	 	US	 	6284125	 	04-Sep-2001	 	17-Apr-1998
	AU-C064
	 	Electrochemical Cell	 	FSG	 	AU	 	705313	 	15-Nov-1996	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	US	 	6179979	 	30-Jan-2001	 	15-Mar-1999
	AU-C141
	 	Electrochemical Cell	 	FSG	 	AU	 	741403	 	02-Aug-1999	 	02-Aug-1999
	AU-C142
	 	Electrochemical Cell	 	FSG	 	AU	 	735132	 	02-Aug-1999	 	02-Aug-1999
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	AU	 	738128	 	15-Nov-1996	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	US	 	6174420	 	16-Jan-2001	 	18-May-1999
	AU-C065
	 	Electrochemical Method	 	FSG	 	AU	 	705165	 	15-Nov-1996	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	IL	 	124494	 	03-Dec-2000	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	RU	 	2174679	 	10-Oct-2001	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	SG	 	53703	 	19-Sep-2000	 	15-Nov-1996
	AU-C080
	 	Electrochemical Method	 	FSG	 	US	 	5942102	 	24-Aug-1999	 	05-Jul-1997
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	AU	 	723768	 	25-Mar-1998	 	25-Mar-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	US	 	6325917	 	04-Dec-2001	 	11-Feb-2000
	AU-C167
	 	Method and device for sampling and analyzing interstitial fluid and whole blood samples	 	FSG	 	WO	 	WO 01/72220	 	04-Oct-2001	 	26-Mar-2001
	AU-C054
	 	Method of Defining an Electrode Area	 	FSG	 	AU	 	693678	 	11-Apr-1996	 	11-Apr-1996
	AU-C054
	 	Method of Defining an Electrode Area	 	FSG	 	SG	 	45676	 	27-Apr-1999	 	11-Apr-1996
	AU-C054
	 	Method of Defining an Electrode Area	 	FSG	 	US	 	5980709	 	09-Sep-1999	 	10-Oct-1997
	AU-C161
	 	Method of Preventing short sampling of a capillary or wicking fill device	 	FSG	 	WO	 	WO 01/723395	 	04-Oct-2001	 	26-Mar-2001
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	AU	 	697214	 	12-Apr-1995	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	US	 	5863400	 	26-Jan-1999	 	24-Feb-1997
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	OWNER	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	USF Filtration & Separations Group Inc	 	FSG	 	 	 	 	 	 	 	 	 	 	 	 

13

 

EXHIBIT A

Sensor Patents Pending

	 	 	 	 	 	 	 	 	 	 	 	 	 
	USF Reference	 	Title	 	Owner	 	Country	 	Application Number	 	Filing Date
	AU-C245
	 	Ambidextrous Strip	 	FSG	 	US	 	 	 	 	 	 
	AU-C089
	 	Analytic Cell	 	FSG	 	CA	 	2264288	 	11-Sep-1997
	AU-C089
	 	Analytic Cell	 	FSG	 	EP	 	97938686.9	 	11-Sep-1997
	AU-C089
	 	Analytic Cell	 	FSG	 	JP	 	513059/1998	 	11-Sep-1997
	AU-C089
	 	Analytic Cell	 	FSG	 	WO	 	PCT/AU97/00599	 	11-Sep-1997
	AU-C244
	 	Electrochemical Cell	 	FSG	 	US	 	09/709968	 	10-Nov-2000
	AU-C056
	 	Electrochemical Cell	 	FSG	 	CA	 	2222525	 	19-Jun-1996
	AU-C056
	 	Electrochemical Cell	 	FSG	 	CN	 	96194874.4	 	19-Jun-1996
	AU-C056
	 	Electrochemical Cell	 	FSG	 	EP	 	96917287.3	 	19-Jun-1996
	AU-C056
	 	Electrochemical Cell	 	FSG	 	JP	 	502421/1997	 	19-Jun-1996
	AU-C056
	 	Electrochemical Cell	 	FSG	 	KR	 	10-1997709488	 	19-Jun-1996
	AU-C056
	 	Electrochemical Cell	 	FSG	 	WO	 	AU96/00365	 	19-Jun-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	BR	 	PI9611514-9	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	CA	 	2236850	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	CN	 	96199077.5	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	EP	 	96937919.7	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	HK	 	99103129.0	 	20-Jul-1999
	AU-C064
	 	Electrochemical Cell	 	FSG	 	IL	 	124495	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	JP	 	518444/1997	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	KR	 	703701/1998	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	MX	 	983881	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	RU	 	98111492	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	SG	 	9802884.8	 	15-Nov-1996
	AU-C064
	 	Electrochemical Cell	 	FSG	 	WO	 	PCT/AU96/00724	 	15-Nov-1996
	AU-C215
	 	Electrochemical Cell	 	FSG	 	US	 	09/618515	 	18-Jul-2000
	AU-C260
	 	Electrochemical Cell	 	FSG	 	IL	 	133994	 	 	 	 
	AU-C279
	 	Electrochemical Cell	 	FSG	 	US	 	09/840624	 	23-Apr-2001
	AU-C317
	 	Electrochemical Cell	 	FSG	 	US	 	 	 	 	 	 
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	AT	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	BE	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	BR	 	 	 	16-Dec-1999
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	CA	 	 	 	 	 	 
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	CH	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	CN	 	99123109.0	 	 	 	 

14

 

EXHIBIT A

	 	 	 	 	 	 	 	 	 	 	 	 	 
	USF Reference	 	Title	 	Owner	 	Country	 	Application Number	 	Filling Date
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	DE	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	DK	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	EP	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	ES	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	FR	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	GB	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	GR	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	HK	 	00107699.9	 	30-Nov-2000
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	IL	 	132089	 	27-Sep-1999
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	IT	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	JP	 	 	 	 	 	 
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	KR	 	10-2001-7014495	 	14-Nov-2001
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	LI	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	MX	 	999175	 	07-Oct-1999
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	NL	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	RU	 	2000104734	 	24-Feb-2000
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	SE	 	99202305.1	 	15-Nov-1996
	AU-C137
	 	Electrochemical Cell (Notch)	 	FSG	 	SG	 	 	 	 	 	 
	AU-C316
	 	Electrochemical cell connector	 	FSG	 	US	 	 	 	 	 	 
	AU-C065
	 	Electrochemical Method	 	FSG	 	BR	 	PI9611513-0	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	CA	 	2236848	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	CN	 	96199076.7	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	EP	 	96937918.9	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	HK	 	99101616.4	 	14-Apr-1999
	AU-C065
	 	Electrochemical Method	 	FSG	 	JP	 	518443/1997	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	KR	 	703700/1998	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	MX	 	983882	 	15-Nov-1996
	AU-C065
	 	Electrochemical Method	 	FSG	 	WO	 	PCT/AU96/00723	 	15-Nov-1996
	AU-C213
	 	Electrochemical method for measuring chemical reaction rates	 	FSG	 	AR	 	P010103342	 	13-Jul-2001
	AU-C213
	 	Electrochemical method for measuring chemical reaction rates	 	FSG	 	MY	 	PI20013295	 	11-Jul-2001
	AU-C213
	 	Electrochemical method for measuring chemical reaction rates	 	FSG	 	TH	 	066874	 	12-Jul-2001
	AU-C213
	 	Electrochemical method for measuring chemical reaction rates	 	FSG	 	TW	 	90117040	 	12-Jul-2001
	AU-C213
	 	Electrochemical method for measuring chemical reaction rates	 	FSG	 	US	 	09/616556	 	14-Jul-2000
	AU-C213
	 	Electrochemical method for measuring chemical reaction rates	 	FSG	 	WO	 	PCT/US01/21314	 	06-Jul-2001
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	AU	 	29124/99	 	11-Mar-1999

15

 

EXHIBIT A

	 	 	 	 	 	 	 	 	 	 	 	 	 
	USF Reference	 	Title	 	Owner	 	Country	 	Application Number	 	Filling Date
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	CA	 	2322757	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	DE	 	99910001.9	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	EP	 	99910001.9	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	ES	 	99910001.9	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	FR	 	99910001.9	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	GB	 	99910001.9	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	HK	 	01103634.5	 	25-May-2001
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	IT	 	99910001.9	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	JP	 	2000-535917	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	NL	 	99910001.9	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	TW	 	88103765	 	11-Mar-1999
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	US	 	09/659470	 	11-Sep-2000
	AU-C131
	 	Heated Electrochemical Cell	 	FSG	 	WO	 	PCT/AU99/00152	 	11-Mar-1999
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	CA	 	2284532	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	DE	 	 	 	 	 	 
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	EP	 	98910522.6	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	ES	 	98910522.6	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	FR	 	98910522.6	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	GB	 	98910522.6	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	IT	 	98910522.6	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	JP	 	543209/1998	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	NL	 	98910522.6	 	25-Mar-1998
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	US	 	09/404119	 	23-Sep-1999
	AU-C094
	 	Improved Electrochemical Cell	 	FSG	 	WO	 	PCT/AU98/00200	 	25-Mar-1998
	AU-C166
	 	Improved Electrochemical Cell	 	FSG	 	US	 	09/568076	 	10-May-2000
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	AU	 	87263/98	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	CA	 	2300406	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	DE	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	EP	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	ES	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	FR	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	GB	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	GR	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	IE	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	IT	 	98938521.6	 	13-Aug-1998

16

 

EXHIBIT A

	 	 	 	 	 	 	 	 	 	 	 	 	 
	USF Reference	 	Title	 	Owner	 	Country	 	Application Number	 	Filing Date
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	JP	 	2000-510018	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	NL	 	98938521.6	 	13-Aug-1998
	AU-C107
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	WO	 	PCT/AU98/00642	 	13-Aug-1998
	AU-C307
	 	Method and Apparatus for Automatic Analysis	 	FSG	 	US	 	09/970461	 	02-Oct-2001
	AU-C167
	 	Method and device for sampling and analyzing interstitial fluid and whole blood samples	 	FSG	 	TW	 	90108732	 	12-Apr-2001
	AU-C167
	 	Method and device for sampling and analyzing interstitial fluid and whole blood samples	 	FSG	 	US	 	09/536235	 	27-Mar-2000
	AU-C167
	 	Method and device for sampling and analyzing interstitial fluid and whole blood samples	 	FSG	 	WO	 	US01/09673	 	26-Mar-2001
	AU-C054
	 	Method of Defining an Electrode Area	 	FSG	 	CA	 	2216911	 	11-Apr-1996
	AU-C054
	 	Method of Defining an Electrode Area	 	FSG	 	EP	 	96908916.8	 	11-Apr-1996
	AU-C054
	 	Method of Defining an Electrode Area	 	FSG	 	JP	 	530573/1996	 	11-Apr-1996
	AU-C054
	 	Method of Defining an Electrode Area	 	FSG	 	WO	 	PCT/AU96/00210	 	11-Apr-1996
	AU-C161
	 	Method of preventing short sampling of a capillary or wicking fill device	 	FSG	 	TW	 	90108733	 	12-Apr-2001
	AU-C161
	 	Method of preventing short sampling of a capillary or wicking fill device	 	FSG	 	US	 	09/536234	 	27-Mar-2000
	AU-C161
	 	Method of preventing short sampling of a capillary or wicking fill device	 	FSG	 	WO	 	US01/09675	 	26-Mar-2001
	AU-C287
	 	Novel Electrochemical Cells	 	FSG	 	US	 	60/328846	 	10-Oct-2001
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	AT	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	BE	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	CH	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	DE	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	DK	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	EP	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	ES	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	FR	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	GB	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	GR	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	IE	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	IT	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	JP	 	526564/1995	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	LU	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	MC	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	NL	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	PT	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	SE	 	95915068.1	 	12-Apr-1995
	AU-C041
	 	Novel Electrochemical Cells	 	FSG	 	WO	 	PCT/AU95/00207	 	12-Apr-1995
	AU-C248
	 	Novel mediation strategy for enzyme linked electrochemical assays	 	FSG	 	US	 	 	 	 	 	 

17

 

EXHIBIT A

	 	 	 	 	 	 	 	 	 	 	 	 	 
	USF Reference	 	Title	 	Owner	 	Country	 	Application Number	 	Filing Date
	AU-C095
	 	Sensor Connection Means	 	FSG	 	AT	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	AU	 	66044/98	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	BE	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	BR	 	PI9807987-5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	CA	 	2284634	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	CH	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	CN	 	98804325.4	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	DE	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	DK	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	EP	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	ES	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	FR	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	GB	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	GR	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	HK	 	00103935.2	 	29-Jun-2000
	AU-C095
	 	Sensor Connection Means	 	FSG	 	IL	 	131980	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	IT	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	JP	 	544532/1998	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	KR	 	7008615/1999	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	MX	 	998659	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	NL	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	RU	 	99122339	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	SE	 	98907775.5	 	20-Mar-1998
	AU-C095
	 	Sensor Connection Means	 	FSG	 	SG	 	9904624-5	 	20-Mar-1998
	AU-C318
	 	Sensor Connection Means	 	FSG	 	US	 	09/399512	 	20-Sep-1999
	AU-C132
	 	Sensor Connection Means Life	 	FSG	 	WO	 	PCT/AU98/00184	 	20-Mar-1998
	AU-C132
	 	Sensor Connection Means Life	 	FSG	 	US	 	to be advised	 	04-Jan-2002
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	AU	 	29136/99	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	CA	 	2322454	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	DE	 	99910013.4	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	EP	 	99910013.4	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	ES	 	99910013.4	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	FR	 	99910013.4	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	GB	 	99910013.4	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	HK	 	01104929.7	 	31-Jul-2001
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	IT	 	99910013.4	 	16-Mar-1999
	AU-C132
	 	Sensor with Improved Shelf Life	 	FSG	 	JP	 	2000-538226	 	16-Mar-1999

18

 

EXHIBIT A

	 	 	 	 	 	 	 	 	 	 	 
	USF Refrence	 	Tittle	 	Owner	 	Country	 	Application Number	 	Filing Date
	AU-C132

	 	Sensor with Improved Shelf Life
	 	FSG
	 	NL
	 	99910013.4 
	 	16-Mar-1999
	AU-C132

	 	Sensor with Improved Shelf Life
	 	FSG
	 	TW
	 	88104370 
	 	19-Mar-1999
	AU-C132

	 	Sensor with Improved Shelf Life
	 	FSG
	 	US
	 	09/664688
	 	19-Sep-2000
	AU-C132

	 	Sensor with Improved Shelf Life
	 	FSG
	 	WO
	 	PCT/AU99/00166
	 	16-Mar-1999
	AU-C322

	 	Direct Immunoassay Sensor
	 	FSG
	 	AU
	 	Invention Disclosure
	 	14-Jan-02
	 

	 	OWNER	 	 	 	 	 	 	 	 
	 

	 	USF Filtration & Separations Group Inc
	 	FSG	 	 	 	 	 	 

19

 

EXHIBIT A

Non Sensor Patents Pending

	 	 	 	 	 	 	 	 	 	 	 
	Case Number	 	Tittle	 	Owner	 	Country	 	Application Number	 	Filing Date
	AU-C199

	 	Anti-oxidant sensor disclosure
	 	FSG
	 	US
	 	09/615691
	 	14-JUl-2000
	AU-C199

	 	Anti-oxidant sensor disclosure
	 	FSG
	 	WO
	 	US01/21961
	 	12-Jul-2001
	AU-C214

	 	Hemoglobin Sensor
	 	FSG
	 	US
	 	09/616512
	 	14-Jul-2000
	AU-C214

	 	Hemoglobin Sensor
	 	FSG
	 	WO
	 	US01/21964
	 	12-Jul-2001
	AU-C198

	 	Immunosensor
	 	FSG
	 	US
	 	09/616433
	 	14-Jul-2000
	AU-C198

	 	Immunosensor
	 	FSG
	 	WO
	 	US01/22202
	 	13-Jul-2000

20

 

EXHIBIT B

Australia

Canada

EPO:

France

Germany

Italy

Netherlands

Spain

United Kingdom

Japan

United States

21exv10w2

 

Exhibit 10.2

	 	 	 	 	 
	

	 	 	 	
LifeScan, Inc. 1000
Gibraltar Drive, Milpitas, CA 95035-6312

Tel: 408-956-4900 Fax: 408-956-4966 www.LifeScan.com

Eric P. Milledge

Company Group Chairman

March 31, 2004

Denis Hanley

Director, Universal Biosensors

RMB 5512 Coachwood Road

Matcham NSW 2250

Australia

Dear Denis,

I am writing to you today to propose amending our current Development and Research Agreement.
This amendment will be effective as of First day of April, 2004 and amends the Development
and Research Agreement (“Agreement”) entered into the 1st day of April, 2002 by
and between Universal Biosensors, Inc., a Delaware corporation having a principal place of
business at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808 (“Universal
Biosensors”) and LifeScan Inc., a California corporation having its principal place of
business at 1000 Gibraltar Drive, Milpitas, California 95035 (“LifeScan”). LifeScan and
Universal Biosensors are sometimes referred to herein individually as a “Party” and
collectively as the “Parties.”

In consideration for the covenants and undertakings set forth herein and in the
Agreement, the Parties hereby agree:

LifeScan has fully satisfied all of its obligations under the Agreement, including, without
limitation, its payment obligations under Article 4 of the Agreement.

Article 1.11 is hereby deleted in its entirety and replaced by the following Article:

1.11 “Term” means a period beginning on April 1st 2002 and extending to
through December 31, 2004 unless extended or sooner terminated by the Parties in
accordance with the provisions of this Agreement.

In the first sentence of Article 2.5, thirty (30) days is hereby replaced with ninety (90)
days.

 

 

Articles 4.1 and 4.2 are hereby deleted in their entirety and replaced by the following
Articles:

4.1 In consideration for the rights, licenses and options granted herein to LifeScan and
for extending the term for the period set forth in Article 1.11, LifeScan shall, during the
remaining term of this Agreement, pay Universal Biosensors

	 	a.	 	Six hundred and twenty-five thousand dollars Australian
($625,000) payable on or before April 15, 2004.
	 
	 	b.	 	Six hundred and twenty-five thousand dollars Australian
($625,000) payable on or before July 1, 2004.
	 
	 	c.	 	Six hundred and twenty-five thousand dollars Australian
($625,000) payable on or before October 1, 2004.

4.2 Any payments due during the remaining term of this Agreement shall be payable to
Universal Biosensors in Australian dollars by wire transfer.

The Parties agree that all other provisions in the Agreement remain effective for the
duration of the new Term of the Agreement.

In witness whereof, LifeScan and Universal Biosensors have caused these present to be signed.

	 	 	 	 	 	 	 	 	 	 	 
	LifeScan, Inc.	 	 	 	Universal Biosensors	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Eric P. Milledge
	 	 	 	By:
	 	/s/ Denis Hanley	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	Eric P. Milledge
	 	 	 	Name:
	 	Denis Hanley	 	 
	Title:

	 	Company Group Chairman
	 	 	 	Title:
	 	Director	 	 

 

 

	 	 	 	 	 
	

	 	 	 	
LifeScan, Inc. 1000 Gibraltar Drive, Milpicas, CA 95035-6312

Tel: 408-263-9789 Fax: 408-946-6070 www.LifeScan.com

December 8, 2004

Denis Hanley

Director, Universal Biosensors

RMB 5512 Coachwood Road

Matcham NSW 2250

Australia

	 	 	 
	Re:

	 	Development and Research Agreement, Dated April 1, 2002 and Amended March 31, 2004

Dear Denis,

In consideration for product and process testing activities associated with the Gemini Project in
the months of November and December, 2004 which have exceeded the scope of our Development and
Research Agreement, LifeScan hereby agrees to pay Universal Biosensors two hundred thousand
dollars U.S. ($200,000) on or before December 31, 2004.

In witness whereof, LifeScan and Universal Biosensors have caused these present to be signed.

	 	 	 	 	 	 	 	 	 	 	 
	LifeScan, Inc.	 	 	 	Universal Biosensors	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ John E. Klopp
	 	 	 	By:
	 	/s/ Denis Hanley	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	John E. Klopp
	 	 	 	Name:
	 	Denis Hanley	 	 
	Title:

	 	Vice President Worldwide

Business Development
	 	 	 	Title:
	 	Director	 	 

 

 

	 	 	 	 	 
	

	 	 	 	
LifeScan, Inc. 1000 Gibraltar Drive, Milpitas, CA 95035-6312 

Tel: 408-263-9789 Fax: 408-946-6070 www.LifeScan.com

December 21, 2004

Denis Hanley

Director, Universal Biosensors

RMB 5512 Coachwood Road

Matcham NSW 2250

Australia

Dear Denis,

I am writing to you today to propose extending our current Development and Research Agreement. This
extension will be effective as of First day of January, 2005 and amends the Development and
Research Agreement (“Agreement”) entered into on the 1st day of April, 2002 and amended
on the 31st day of March, 2004 by and between Universal Biosensors, Inc., a Delaware corporation
having a principal place of business at 2711 Centerville Road, Suite 400, Wilmington, Delaware
19808 (“Universal Biosensors”) and LifeScan Inc., a California corporation having its principal
place of business at 1000 Gibraltar Drive, Milpitas, California 95035 (“LifeScan”). LifeScan and
Universal Biosensors are sometimes referred to herein individually as a “Party” and collectively as
the “Parties.”

In consideration for the covenants and undertakings set forth herein and in the
Agreement, the Parties hereby agree:

LifeScan has fully satisfied all of its obligations under the Agreement, including, without
limitation, its payment obligations under Article 4 of the Agreement.

Article 1.11 is hereby deleted in its entirety and replaced by the following Article:

1.11 “Term” means a period beginning on April 1st 2002 and extending through
December 31, 2005 unless extended or sooner terminated by the Parties in accordance with
the provisions of this Agreement.

 

 

Articles 4.1 and 4.2 are hereby deleted in their entirety and replaced by the following
Articles:

4.1 In consideration for the rights, licenses and options granted herein to LifeScan and
for extending the term for the period set forth in Article 1.11, LifeScan shall, during the
remaining term of this Agreement, pay Universal Biosensors

	 	a.	 	Seven hundred and thirty thousand dollars Australian ($730,000) payable
on or before January 15, 2005.
	 
	 	b.	 	Seven hundred and fifty-five thousand dollars Australian
($755,000) payable on or before April 1, 2005.
	 
	 	c.	 	Six hundred and twenty-five thousand dollars Australian
($625,000) payable on or before July 1, 2005.
	 
	 	d.	 	Six hundred and twenty-five thousand dollars Australian ($625,000) payable on or
before October 1, 2005.

4.2 Any payments due during the remaining term of this Agreement shall be payable to
Universal Biosensors in Australian dollars by wire transfer.

The Parties agree that all other provisions in the Agreement remain effective for the
duration of the new Term of the Agreement.

In witness whereof, LifeScan and Universal Biosensors have caused these present to be signed.

	 	 	 	 	 	 	 	 	 	 	 
	LifeScan, Inc.	 	 	 	Universal Biosensors	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Eric P. Milledge
	 	 	 	By:
	 	/s/ Denis Hanley	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	Eric P. Milledge
	 	 	 	Name:
	 	Denis Hanley	 	 
	Title:

	 	Company Group Chairman
	 	 	 	Title:
	 	Director	 	 

 

 

	 	 	 	 	 
	

	 	 	 	
 LifeScan, Inc. 1000
Gibraltar Drive, Milpitas, CA 95035-6312 

Tel: 408-263-9789 Fax: 408-946-6070 www.LifeScan.com

December 7, 2005

Andrew Denver

Chairman

Universal Biosensors Inc

27, Woodville Ave

Wahroonga NSW 2076

Australia

Dear Andrew,

I am writing to you to propose amending our current Development and Research Agreement.

This amendment will be effective as of the date of signing and amends the Development & Research
Agreement (“Agreement”) entered on or about 1 April, 2002 and amended on March 31, 2004 and
December 21, 2004 by and between Universal Biosensors, Inc. a Delaware corporation having a
principal place of business at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808
(“Universal Biosensors”) and LifeScan Inc., a California corporation having its principal place of
business at 1000 Gibraltar Drive, Milpitas, California 95035 (“LifeScan”). LifeScan and Universal
Biosensors are sometimes referred to herein individually as a “Party” and collectively as the
“Parties.”

In consideration for the covenants and undertakings set forth herein and in the
Agreement, the Parties hereby agree:-

Article 1.5 is hereby deleted in its entirety and replaced by the following Section:

     1.5 “LIFESCAN’s Fields means:

	 	a)	 	the measurement of analytes for purposes of diagnosing,
managing, monitoring, prognosticating, treating or curing diabetes; and
	 
	 	b)	 	the measurement of glucose in humans for any other
purpose, including, without limitation, tight glycemic control.

Article 1.11 is hereby deleted in its entirety and replaced by the following Section:

     1.11
“Term” means a period or periods set forth in Article 8.1

Article 2.5 is deleted in its entirety and replaced by the following Section:

Page 1 of 3

 

 

	 	2.5	 	Promptly at the end of the Term, UNIVERSAL BIOSENSORS shall transfer
to LIFESCAN all Joint Know-How existing as at the end of the Term. Such
information shall include, without limitation, copies of all relevant data,
drawings, notebooks and samples. In addition, UNIVERSAL BIOSENSORS shall offer to
LIFESCAN such consultation with UNIVERSAL BIOSENSORS employees as may be
reasonably necessary to permit LIFESCAN and its agents to continue work on the
Program. After termination of the Agreement, such consultation shall be at
LIFESCAN’s cost.

Article 4.1 is deleted in its entirety and replaced by the following Section:

	 	4.1	 	In consideration for the rights, licenses, and options granted herein
to LIFESCAN, LIFESCAN shall make payments to UNIVERSAL BIONSENSORS in
accordance with the provisions of Exhibit D.

Article 4.2 is deleted in its entirety and replaced by the following Article:

	 	4.2	 	Any payments due during the Term of this Agreement shall be payable to
Universal Biosensors in United States dollars by wire transfer.

Article 8.1 is deleted in its entirety and replaced by the following Section:

	 	8.1	 	Subject to Section 9.1, this Agreement shall be effective for an initial
term commencing on the Effective Date until December 31st, 2006.
After December 31st, 2006, this Agreement shall automatically renew
for successive one (1) year periods on the same terms and
conditions of this Agreement,
unless either party has given to the other party prior written notice of termination
not less than 9 months prior to the end of the relevant one year period, in which case
the Agreement will terminate at the end of the relevant one year period.
	 
	 	8.2	 	Notwithstanding anything to the contrary in Article 8.1, if either party to
this Agreement materially defaults or materially breaches the terms of this Agreement
other than by reason of force majeure, the other party shall have the right to
terminate this Agreement by giving written notice to that effect to the defaulting
party thirty (30) days in advance of the date of termination specified in the notice.
However, if the default or breach is corrected or made good by the party receiving
notice within thirty (30) days after the notice of termination has been received, this
Agreement shall be canceled but shall remain in full force and effect.

The Parties agree that all other provisions in the Agreement remain effective.

Page 2 of 3

 

 

In witness whereof, LifeScan and Universal Biosensors have caused these present to be signed.

AGREED AND ACCEPTED TO:

	 	 	 	 	 	 	 	 	 	 	 
	UNIVERSAL BIOSENSORS INC	 	 	 	LIFESCAN, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Andrew Denver
	 	 	 	By:
	 	/s/ Eric P. Milledge	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	Andrew Denver
	 	 	 	Name:
	 	Eric P. Milledge	 	 
	Title:

	 	Chairman
	 	 	 	Title:
	 	Company Group Chairman	 	 
	Date:

	 	Jan 9 2006
	 	 	 	Date:
	 	01/04/06	 	 

Page 3 of 3

 

 

EXHIBIT D

In consideration for the rights, licenses, and options granted herein to LIFESCAN, from
January 1, 2006 LIFESCAN shall make payments to UNIVERSAL BIOSENSORS of five hundred thousand
DOLLARS US (US $500,000.00) within thirty (30) days of the beginning of each calendar quarter
during the Term. Any payments due hereunder shall be payable to UNIVERSAL BIOSENSORS in United
States Dollars by wire transfer.

 

 

Exhibit 10.2

DEVELOPMENT AND RESEARCH AGREEMENT

     THIS DEVELOPMENT AND RESEARCH AGREEMENT (the
“Agreement”) is made and entered into this 1st day of April, 2002 (the “Effective Date”)
by and between Universal Biosensors, a Delaware corporation having a principal place of
business at 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808
(“UNIVERSAL BIOSENSORS”) and LifeScan, Inc., a California corporation having its
principal place of business at 1000 Gibraltar Drive, Milpitas, California 950935
(“LIFESCAN”). LIFESCAN and UNIVERSAL BIOSENSORS are sometimes referred
to herein individually as a “PARTY” and collectively as the “PARTIES.”

WITNESSETH

     WHEREAS, UNIVERSAL BIOSENSORS has the expertise and will have the facilities to conduct
research programs relating to a variety of fields; and

     WHEREAS, LIFESCAN desires to fund a portion of the research to be conducted by UNIVERSAL
BIOSENSORS;

     NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, the
parties agree to the following:

Article 1. Definitions.

     As used herein, the following terms shall be defined as follows:

     1.1 “Affiliate” means any entity that directly or indirectly controls, is controlled by, or is
under common control with a party to the Agreement. “Control” shall mean the possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of the
entity, whether through the ownership of voting securities, by contract or otherwise.

1

 

     1.2 “Development” means a modification of a component, device, material, or process.

     1.3 “Field” means a field-of-use.

     1.4 “Joint Know-How” means all information, technology, and Developments developed jointly by,
or at the joint instruction of, employees or agents of both of the Parties in the course of
carrying out the Program including, without limitation, ideas, techniques, processes, practices,
trade secrets, methods, knowledge, know-how, skill, expertise, test data and results, analytical
and quality control data, results or descriptions, devices, delivery systems, compounds,
compositions of matter, and materials and all improvements thereto.

     1.5 “LIFESCAN Field” means: a.) measurement of analytes for purposes of diagnosing, managing,
monitoring, prognosticating, treating, or curing diabetes: b.) measurement of blood coagulation;
and c.) measurement for purposes of diagnosing, managing, monitoring, prognosticating, treating, or
curing blood coagulopathies, excluding the measurement of total hemoglobin.

     1.6 “LIFESCAN’s Acquired Know-How” means all know-how, data, and information acquired from USF
Filtration and Separations Group Inc. (“FSG”) by LIFESCAN and related to the LIFESCAN Acquired
Patents.

     1.7 “LIFESCAN’s Acquired Patents” means those applications and patents acquired by
LIFESCAN from FSG and identified on Exhibit A attached hereto and made a part hereof.

     1.8 “Program” means research conducted by UNIVERSAL BIOSENSORS in the LIFESCAN Field jointly
with, or as directed by, LIFESCAN in the areas set forth on Exhibit B attached hereto and made a
part hereof.

2

 

     1.9 “UNIVERSAL BIOSENSORS’ Fields” means all Fields outside of LIFESCAN’s Field.

     1.10 “UNIVERSAL BIOSENSORS’ Know-How” means all information, technology and Developments
developed solely by, or at the sole instruction, of an employee or agent of UNIVERSAL BIOSENSORS in
the course of the Program including, without limitation, ideas, techniques, processes, practices,
trade secrets, methods, knowledge, know-how, skill, expertise, test data and results, analytical
and quality control data, results or descriptions, devices, delivery systems, compounds,
compositions of matter, and materials and all improvements thereto.

     1.11 “Term” means a period beginning on the Effective Date and extending for a period of two
(2) years unless extended or sooner terminated by the Parties in accordance with Article 8.

Article 2. Program.

     2.1 During the Term, UNIVERSAL BIOSENSORS shall use its best efforts to perform the
Program and any other areas mutually agreed upon by the Parties.

	 	a.)	 	Details of the work to be carried out in each of the areas set forth on
Exhibit B shall be mutually agreed upon in writing by the Parties.
	 
	 	b.)	 	UNIVERSAL BIOSENSORS shall furnish to LIFESCAN written calendar quarterly
reports disclosing the progress of the Program, data and summaries of research
findings, Joint Know-How and UNIVERSAL BIOSENSORS Know-How conceived or reduced to
practice during the subject quarter, and goals and objectives for the subsequent
quarter.
	 
	 	c.)	 	LIFESCAN shall have reasonable access to any UNIVERSAL BIOSENSORS’ facilities
involved in work on the Program and, in addition, UNIVERSAL BIOSENSORS shall provide
to LIFESCAN such

3

 

	 	 	 	information regarding the results of the Program as LIFESCAN may reasonably request
to enable LIFESCAN to enjoy the rights granted herein pursuant to Article 3.
	 
	 	d.)	 	UNIVERSAL BIOSENSORS will manage the Program in consultation with LIFESCAN
and any substantial modifications to the Program will be subject to the written
approval of LIFESCAN.

     2.2 Supervision of the Program shall be provided by a steering committee (the “Steering
Committee”) that consists of two persons appointed by each party and the Vice President of R & D of
LIFESCAN, who will be the chairperson of the Steering Committee. The Steering Committee shall meet
about every three (3) months at mutually agreed locations, by video conference, or as otherwise
mutually agreed to by the parties.

     2.3 The Parties anticipate that work on the Program will be performed at UNIVERSAL BIOSENSORS’
facility in Melbourne, Australia.

     2.4 UNIVERSAL BIOSENSORS shall assist LIFESCAN:

	 	a.)	 	as is reasonably necessary in obtaining regulatory approvals
in any country in which LIFESCAN desires to sell a product that is developed,
or any portion of which is developed, in the course of carrying out the
Program; and
	 
	 	b.)	 	as is deemed necessary by LIFESCAN’s patent attorneys in
filing, prosecuting, maintaining, and defending LIFESCAN’s Acquired Patents.

During the Term, such assistance shall be at no cost to LIFESCAN except for the costs of travel and
accommodations for travel requested by LIFESCAN. After expiration or termination of the Agreement,
such assistance shall be at LIFESCAN’s cost.

     2.5 If the Term extends beyond two (2) years from the Effective Date, then notwithstanding any
other term of this Agreement, LIFESCAN shall have the option, in

4

 

its sole and absolute discretion, to terminate UNIVERSAL BIOSENSORS’ responsibility for
performing work on the Program at any time by providing written notice to UNIVERSAL BIOSENSORS.
UNIVERSAL BIOSENSORS’ responsibility for performing work on the Program, and LIFESCAN’s
responsibility for funding such work, shall terminate thirty (30) days after such notice. Promptly
after the end of the Term either if it extends only for two (2) years after the Effective Date or
if the Term extends beyond that two (2) years and is terminated on thirty (30) days notice as
provided in this Section 2.5, UNIVERSAL BIOSENSORS shall transfer to LIFESCAN all Joint Know-How
existing as of the end of the Term. Such information shall include, without limitation, copies of
all relevant data, drawings, notebooks, and samples. In addition, UNIVERSAL BIOSENSORS shall offer
to LIFESCAN such consultation with UNIVERSAL BIOSENSORS employees as may be reasonably necessary to
permit LIFESCAN and its agents to continue work on the Program. Such consultation shall be at no
cost to LIFESCAN except for costs of necessary travel and accommodations for UNIVERSAL BIOSENSORS’
employees.

     2.6 As to the Joint Know-How, the parties agree as follows:

	 	a.)	 	LIFESCAN will, at LIFESCAN’s sole discretion, accept liaison
and financial responsibility for:
	 
	 	 	 	(i.) preparation by a patent attorney in independent practice nominated
by LIFESCAN and approved by UNIVERSAL BIOSENSORS of a patent application
or applications on the patentable aspects of the Joint Know-How;

(ii.) filing upon execution by the inventors of such application or
applications at least in the those countries listed on Exhibit C (the
“Jurisdictions”) attached hereto and made a part hereof provided that
UNIVERSAL BIOSENSORS may elect, at its own expense, to file the
application or applications in additional countries; and

(iii.) prosecution by the attorney of the application or applications to
allowance or to the point of necessary appeal from a final rejection by an
examiner in the Jurisdictions.

5

 

	 	b.)	 	Except as may be later separately agreed upon by the parties
in writing, LIFESCAN does not accept responsibility for:
	 
	 	 	 	(i.) filing or prosecution of any appeal from a final rejection by an
examiner in any of the Jurisdictions of any patent application; or
	 
	 	 	 	(ii.) the conduct of any interference in which an application or patent
may become involved.
	 
	 	c.)	 	LIFESCAN will furnish UNIVERSAL BIOSENSORS copies of;
	 
	 	 	 	(i.) any applications filed pursuant to paragraph 2.6 a.)(ii.);
	 
	 	 	 	(ii.) any substantive office actions received from any of the
Jurisdictions, pertaining to the applications filed pursuant to paragraph
2.6a.)(ii.); and
	 
	 	 	 	(iii.) any substantive responses to office actions filed pursuant to
subparagraph 2.6a.)(iii.).
	 
	 	d.)	 	UNIVERSAL BIOSENSORS shall assist, as is deemed necessary by
LIFESCAN, in preparing, filing, and prosecuting the applications filed
pursuant to this Section 2.6 and maintaining and defending the patents issuing
therefrom. During the Term, such assistance shall be at no cost to LIFESCAN
except for the costs of travel and accommodations for travel requested by
LIFESCAN. After expiration or termination of the Agreement, such assistance
shall be at LIFESCAN’s cost.
	 
	 	e.)	 	In the event that LIFESCAN elects not to proceed with the
filing or prosecution of any application under this Section 2.6,

6

 

	 	 	 	UNIVERSAL BIOSENSORS shall have the right at any time thereafter and by
written notice to LIFESCAN to assume and continue at its own expense for,
as applicable, any or all of filing, prosecution, appealing or conducting
any interference of the application. Upon receipt by LIFESCAN of such
notice, LIFESCAN shall:

(i.) be relieved of all further financial and other responsibility in
respect to the application;
	 
	 	 	 	(ii.) shall have no further rights thereto in all countries for which
UNIVERSAL BIOSENSORS has assumed the payments;
	 
	 	 	 	(iii.) shall enter into such assignments or other reasonably necessary
documents in respect thereto in all countries for which UNIVERSAL
BIOSENSORS assumes financial responsibility so as to properly vest
ownership and the right to prosecute the application in UNIVERSAL
BIOSENSORS or its nominee; and
	 
	 	 	 	(iv.) shall provide to UNIVERSAL BIOSENSORS the file history of the
application in LIFESCAN’s possession.
	 
	 
	 	f.)	 	Upon issuance of any patents resulting from applications
filed pursuant to paragraph 2.6a.)(ii.), LIFESCAN will accept responsibility
for payment of maintenance fees for the jurisdictions and other countries
elected by LIFESCAN. However, LIFESCAN shall have the right at any time to
discontinue the payment of any or all maintenance fees in any or all such
countries. In the event LIFESCAN discontinues such maintenance payments,
UNIVERSAL BIOSENSORS may, at its option and by written

7

 

	 	 	 	notice to LIFESCAN, maintain the patent at its own expense and license it
to third parties. Upon receipt by LIFESCAN of such notice, LIFESCAN;
	 
	 	 	 	(i.) shall be relieved of all further financial and other responsibility
in respect to the patent at issue;
	 
	 	 	 	(ii.) shall have no further rights thereto in all countries for which
UNIVERSAL BIOSENSORS has assumed the payments;
	 
	 	 	 	(iii.) shall enter into assignments or other reasonably necessary
documents in respect thereto in all countries for which UNIVERSAL
BISOSENSORS assumes financial responsibility so as to properly vest
ownership and the right to maintain the patent in UNIVERSAL BIOSENSORS or
its nominee; and
	 
	 	 	 	(iv.) shall provide to UNIVERSAL BIOSENSORS the file histories of the
patent in LIFESCAN’s possession.

     2.7 As to the UNIVERSAL BIOSENSORS Know-How, the parties agree as follows:

	 	a.)	 	LIFESCAN will, at LIFESCAN’s sole discretion, accept liaison
and financial responsibility for:
	 
	 	 	 	(i.) preparation by a patent attorney in independent practice nominated
by LIFESCAN and approved by UNIVERSAL BIOSENSORS of a patent application
or applications, on the patentable aspects of the UNIVERSAL BIOSENSORS
Know-How, that is directed to subject matter within the LIFESCAN Field or
filed as a continuation or continuation-in-part of one or more of

8

 

	 	 	 	LIFESCAN’s Acquired Patents and is directed to subject matter within the
LIFESCAN Field and;

	 	 	 	(ii.) filing upon execution by the inventors of such application or
applications at least in the Jurisdictions, provided that UNIVERSAL
BIOSENSORS may elect, at its own expense, to file the application or
applications in additional countries; and

(iii.) prosecution by the attorney of the application or applications to
allowance or to the point of necessary appeal from a final rejection by an
examiner in the Jurisdictions.
	 
	 	b.)	 	Except as may be later separately agreed upon by the parties
in writing, LIFESCAN does not accept responsibility for:
	 
	 	 	 	(i.) filing or prosecution of any appeal from a final rejection by an
examiner in any of the Jurisdictions of any patent application; or

(ii.) the conduct of any interference in which an application or
applications may become involved.
	 
	 	c.)	 	LIFESCAN will furnish UNIVERSAL BIOSENSORS copies of;
	 
	 	 	 	(i.) any applications filed pursuant to paragraph 2.7 a.)(ii.);
	 
	 	 	 	(ii.) any substantive office actions received from any of the
Jurisdictions, pertaining to the applications filed pursuant to paragraph
2.7a.)(ii.); and
	 
	 	 	 	(iii.) any substantive responses to office actions filed pursuant to
subparagraph 2.7a.)(iii.).
	 
	 	d.)	 	UNIVERSAL BIOSENSORS shall assist, as is deemed necessary by
LIFESCAN, in preparing, filing, and prosecuting the applications

9

 

	 	 	 	filed pursuant to this Section 2.7 and maintaining and defending the
patents issuing therefrom. During the Term, such assistance shall be at no
cost to LIFESCAN except for the costs of travel and accommodations for
travel requested by LIFESCAN. After expiration or termination of the
Agreement, such assistance shall be at LIFESCAN’s cost.

	 	e.)	 	In the event that LIFESCAN elects not to proceed with the
filing or prosecution of any application under this Section 2.7, respectively,
UNIVERSAL BIOSENSORS shall have the right at any time thereafter and by
written notice to LIFESCAN to assume and continue at its own expense filing,
prosecution, or both of the application. Upon receipt by LIFESCAN of such
notice, LIFESCAN:
	 
	 	 	 	(i.) shall be relieved of all further financial and other responsibility
in respect to the application;
	 
	 	 	 	(ii.) shall have no further rights thereto in all countries for which
UNIVERSAL BIOSENSORS has assumed the payments;
	 
	 	 	 	(iii.) shall enter into such assignments or other reasonably necessary
documents in respect thereto in all countries for which UNIVERSAL
BIOSENSORS assumes financial responsibility so as to properly vest
ownership and the right to prosecute the application in UNIVERSAL
BIOSENSORS or its nominee; and
	 
	 	 	 	(iv.) shall provide to UNIVERSAL BIOSENSORS the file histories of the
application in LIFESCAN’s possession.

10

 

	 	f.)	 	Upon issuance of any patents resulting from applications
filed pursuant to paragraph 2.7a.)(ii.), LIFESCAN will accept responsibility
for payment of maintenance fees for the jurisdictions and all other countries
elected by LIFESCAN. However, LIFESCAN shall have the right at any time to
discontinue the payment of any or all maintenance fees in any or all such
countries. In the event LIFESCAN discontinues such maintenance payments,
UNIVERSAL BIOSENSORS may, at its option and by written notice to LIFESCAN,
maintain the patent at its own expense and license it to third parties. Upon
receipt by LIFESCAN of such notice, LIFESCAN:
	 
	 	 	 	(i.) shall be relieved of all further financial and other responsibility
in respect to the patent at issue;
	 
	 	 	 	(ii.) shall have no further rights thereto in all countries for which
UNIVERSAL BIOSENSORS has assumed the payments;
	 
	 	 	 	(iii.) shall enter into such assignments or other reasonably necessary
documents in respect thereto in all countries for which UNIVERSAL assumes
financial responsibility so as to properly vest ownership and the right to
maintain the patent in UNIVERSAL BIOSENSORS or its nominee; and
	 
	 	 	 	(iv.) shall provide to UNIVERSAL BIOSENSORS the file histories of the
patent in LIFESCAN’s possession.

Article 3. Rights; Licenses; Options.

11

 

     3.1 All right, title and interest in and to the Joint-Know-How shall be owned solely by
LIFESCAN.

     3.2 LIFESCAN hereby grants to UNIVERSAL BIOSENSORS and UNIVERSAL BIOSENSORS accepts a
perpetual, royalty-free, paid-up, exclusive, worldwide right and license, with the right to
sublicense, in UNIVERSAL BIOSENSORS’ Fields to make, have made, use, and sell under and otherwise
exploit in any way the Joint Know-How and all patent applications directed to the Joint Know-How
and patents issuing therefrom.

     3.3 All right, title, and interest in and to UNIVERSAL BIOSENSORS Know-How shall be owned by
UNIVERSAL BIOSENSORS.

     3.4 UNIVERSAL BIOSENSORS hereby grants to LIFESCAN, and LIFESCAN accepts, a perpetual,
royalty-free, paid-up, exclusive, worldwide right and license, with the right to sublicense, in the
LIFESCAN Field to make, have made, use, sell under and otherwise exploit in any way the UNIVERSAL
BIOSENSORS Know-How and all patent applications directed to UNIVERSAL BIOSENSORS Know-How and any
patents issuing therefrom.

     3.5 It is acknowledged by the Parties that, during the Term and thereafter, UNIVERSAL
BIOSENSORS will be conducting research and development in one or more of the UNIVERSAL BIOSENSORS’
Fields utilizing LIFESCAN’s Acquired Know-How, LIFESCAN’s Acquired Patents, or both. In the event
that, during the Term, UNIVERSAL BIOSENSORS make a Development in any of the UNIVERSAL BIOSENSORS’
Fields that UNIVERSAL BIOSENSORS desires to license or sublicense to third parties in a UNIVERSAL
BIOSENSORS’ Field, then during the Term UNIVERSAL BIOSENSORS shall promptly disclose to LIFESCAN in
writing full details of such Development.

12

 

	 	a.)	 	Within sixty (60) days after receipt of the full details, LIFESCAN may notify
UNIVERSAL BIOSENSORS of its interest in licensing the Development in the Field, in
which case UNIVERSAL BIOSENSORS shall enter into good faith negotiations with LIFESCAN
regarding such a license and, during the negotiations, shall not offer to any third
party a license or negotiate with any third party, worldwide, with respect to the
sublicense of that Development in the relevant Field.
	 
	 	b.)	 	If LIFESCAN fails to notify UNIVERSAL BIOSENSORS of its interest, or if no
agreement is reached by the parties within one hundred and twenty (120) days after
negotiations begin, then UNIVERSAL BIOSENSORS may offer a license of the Development
in the relevant Field to a third party; provided, however, that
UNIVERSAL BIOSENSORS shall not enter into a license with a third party on terms more
favorable to the third party than those last offered to LIFESCAN. Unless UNIVERSAL
BIOSENSORS believes that the terms offered to the third party are clearly less
favorable to that party than were the terms last offered to LIFESCAN, UNIVERSAL
BIOSENSORS shall seek the advice of a qualified but disinterested expert to determine
whether the terms offered to the third party are more or less favorable than those
last offered to LIFESCAN.
	 
	 	c.)	 	Before terms are offered to a third party, it must first be determined that
no substantial progress had been made in the Development to be licensed subsequent to
the time that the Development was described to LIFESCAN. If substantial progress has
been made, then the full details of the progress must first be described and the
Development offered to LIFESCAN, as set forth above; provided,
however, that in granting a license to the third party when permitted under
subparagraph b.), the license may confer automatic rights to enhancements or
modifications to Developments without the need to make any further offers to LIFESCAN

13

 

     3.6 To enable UNIVERSAL BIOSENSORS to undertake the Program as provided herein, LIFESCAN
grants for the duration of the Program and UNIVERSAL BIOSENSORS accepts a limited, royalty-free,
non-exclusive license to use the LIFESCAN Acquired Patents and LIFESCAN Acquired Know-How in the
LIFESCAN Field for the research and development activities to be carried out in accordance with the
Program together with the right to grant a sublicense to UNIVERSAL BIOSENSORS’ subsidiary,
Universal Biosensors Pty. Limited (“Subsidiary”), whose facility may undertake the Program as a
contractor to UNIVERSAL BIOSENSORS.

	 	a.)	 	In the event that UNIVERSAL BIOSENSORS grants a sublicense to
its Subsidiary, UNIVERSAL BIOSENSORS shall be responsible for obtaining
assignments from the employees of the Subsidiary assigning the rights in any
intellectual property conceived by the Subsidiary employee in carrying out the
Program to UNIVERSAL BIOSENSORS.
	 
	 	b.)	 	UNIVERSAL BIOSENSORS shall be fully responsible for the
performance of the Subsidiary as contractor and sublicensee.

Article 4. Payments.

     4.1 In consideration for the rights, licenses, and options granted herein to LIFESCAN,
LIFESCAN shall make payments to UNIVERSAL BIOSENSORS of TWO HUNDRED AND FIFTY THOUSAND DOLLARS US
(US $250,000.00) within thirty (30) days of the beginning of each calendar quarter during the Term.

     4.2 Any payments due hereunder shall be payable to UNIVERSAL BIOSENSORS in United States
dollars by wire transfer.

Article 5. Infringement.

     5.1 UNIVERSAL BIOSENSORS and LIFESCAN shall each give prompt notice to one another of any
infringement of Joint Know-How or UNIVERSAL BIOSENSORS’ Know-How by third parties as may come to
its respective knowledge.

14

 

     5.2 LIFESCAN shall have the right, but not the obligation, to pursue legal action against
infringement of the UNIVERSAL BIOSENSORS’ Know-How or any patent directed to any of the UNIVERSAL
BIOSENSORS’ Know-How in the LIFESCAN Field by third parties, including defending any declaratory
judgment action. UNIVERSAL BIOSENSORS shall cooperate with LIFESCAN and provide such non-monetary
assistance as LIFESCAN may reasonably request in connection with such action. Further, UNIVERSAL
BIOSENSORS shall have the right to participate in and be represented by independent counsel in such
action at its own expense. LIFESCAN shall incur no liability to UNIVERSAL BIOSENSORS as a
consequence of such litigation or any resulting unfavorable decision including any decision holding
any patent directed to any of the UNIVERSAL BIOSENSORS’ Know-How invalid or unenforceable.

     5.3 UNIVERSAL BIOSENSORS shall have the right, but not the obligation, to pursue legal action
against infringement of the Joint Know-How or any patent directed to any of the Joint Know-How in
the UNIVERSAL BIOSENSORS’ Field by third parties, including defending any declaratory judgment
action. LIFESCAN shall cooperate with UNIVERSAL BIOSENSORS and provide such non-monetary assistance
as UNIVERSAL BIOSENSORS may reasonably request in connection with such action. Further, LIFESCAN
shall have the right to participate in and be represented by independent counsel in such action at
its own expense. UNIVERSAL BIOSENSORS shall incur no liability to LIFESCAN as a consequence of
such litigation or any resulting unfavorable decision including any decision holding any patent
directed to any of the Joint Know-How invalid or unenforceable.

Article 6. Confidentiality.

     6.1 All confidential information provided by one Party to the other shall be marked as such
and maintained confidential by the recipient during the Term of this Agreement and for a period of
three (3) years following termination or expiration of this Agreement. Confidential information
may be used by the recipient only for the purposes of the Agreement. Such purposes shall include,
without limitation, activities that are

15

 

necessary for the development and marketing of products. Confidential information disclosed
orally by one Party to the other shall be reduced to written form and marked “Confidential” and
sent to the other Party within thirty (30) days after the oral disclosure. The receiving Party
shall guard all such confidential information with at least the same level of care as it guards its
own.

     6.2 Notwithstanding the foregoing, the receiving Party shall be relieved of the
confidentiality obligations herein and shall not be prevented by this Agreement from using any
information received by it from the disclosing Party if:

	 	a.)	 	the information was previously known to the receiving Party;
	 
	 	b.)	 	the information is or becomes generally available to the
public through no fault of the receiving Party, including information
disclosed as a result of either or both publication or laying open for
inspection by the public of any patent applications that the disclosing Party
may file;
	 
	 	c.)	 	the information is acquired in good faith in the future by
the receiving Party from a third Party who is not under an obligation of
confidence to the disclosing Party with respect to such information; or
	 
	 	d.)	 	the information independently developed by or for the
receiving Party without benefit of confidential information received from the
disclosing Party.

     6.3 During the term of this Agreement, UNIVERSAL BIOSENSORS and LIFESCAN each agree not to
disclose information that relates to the Program to any third party without prior written consent,
which consent shall not be unreasonably withheld; provided, however, that the
parties may disclose such information to persons in their respective businesses with a need to know

     6.4 During the Term of this Agreement, UNIVERSAL BIOSENSORS and LIFESCAN each agree not to
disclose the specific terms of this Agreement to any third

16

 

party without prior written consent unless such disclosure: a.) is required by statute, law,
or the requirement of any securities exchange to make such disclosure; and b.) confidential
treatment of the disclosed terms is requested by the disclosing party.

Article 7. Warranty.

     7.1 UNIVERSAL BIOSENSORS warrants that it has the ability to enter into the Agreement, that
there are no outstanding written or oral agreements to which UNIVERSAL BIOSENSORS is a party that
are inconsistent with the Agreement, and that it will not, during the Term, enter into any written
or oral agreements in conflict with the Agreement. Nothing herein shall constitute a warranty that
LIFESCAN can practice the Joint Know-How or UNIVERSAL BIOSENSORS’ Know-How or any Development free
from all third party patent rights.

     7.2 UNIVERSAL BIOSENSORS warrants that it has entered into agreements with its employees to
assign to UNIVERSAL BIOSENSORS their rights in and to all Joint Know-How, UNIVERSAL BIOSENSORS’
Know-How, and all inventions arising therefrom as well as patents and patent applications directed
to such inventions. UNIVERSAL BIOSENSORS also warrants that it will enforce the same to ensure
that UNIVERSAL BIOSENSORS has perfected its title to the Joint or UNIVERSAL BIOSENSORS’ Know-How,
all inventions arising therefrom, as well as patents and patent applications directed to such
inventions. Furthermore, UNIVERSAL BIOSENSORS warrants that: a.) it has caused or will cause all
additional personnel performing work pursuant to the Program, including any subcontractors, to
execute similar agreements with respect to rights in and to all Joint Know-How, UNIVERSAL
BIOSENSORS’ Know-How, and all inventions arising therefrom as well as all patents and patent
applications directed to such inventions; and b.) warrants that it will enforce such agreements to
ensure that UNIVERSAL BIOSENSORS has perfected its title thereto.

     7.3 LIFESCAN warrants that it has the ability to enter into this Agreement, that there are no
outstanding written or oral agreements to which LIFESCAN is a party

17

 

that are inconsistent with the Agreement, and that it will not, while the Agreement is in
force, enter into any written or oral agreement in conflict with the Agreement.

Article 8. Term and Termination.

     8.1 Subject to Section 9.1, this Agreement shall be effective for the Term and shall continue
in full force and effect unless terminated by operation of any provision herein. The Term may be
extended by the written, mutual agreement of the Parties.

     8.2 If either party to this Agreement materially defaults or materially breaches the terms of
this Agreement other than by reason of force majeure, the other party shall have the right to
terminate this Agreement by giving written notice to that effect to the defaulting party thirty
(30) days in advance of the date of termination specified in the notice. However, if the default
or breach is corrected or made good by the party receiving notice within thirty (30) days after the
notice of termination has been received, this Agreement shall not be canceled but shall remain in
full force and effect.

Article 9. General Provisions.

     9.1 Surviving Provisions. The provisions of paragraphs 2.6d.) through f.) and 2.7d.)
through f.), Sections 2.4, 2.5, 3.1, 3.2, 3.3, 3.4 3.5, and 9.10, and Articles 5, 6, and 7 shall
survive the expiration or termination of this Agreement.

     9.2 Notice. All communications, reports, payments and notices shall be effective when
delivered personally, or sent by facsimile transmission, air courier, or registered or certified
mail, return receipt requested, and addressed as follows:

     If to UNIVERSAL BIOSENSORS:

Beth Hughes

Venable Attorneys at Law

18

 

8010 Towers Crescent Drive

Suite 300

Vienna, Virginia 22181

USA

With a copy to:

Mr. Denis Hanley

Fax: 612 4365 5872

	 	 	 
	If to LIFESCAN:

	 	LIFESCAN, INC.
	 

	 	1000 Gibraltar Drive
	 

	 	Milpitas, CA 95035
	 

	 	Attn: President
	 

	 	Fax No.: (408) 956-4701
	 
	 	 
	With copy to:

	 	Chief Patent Counsel
	 

	 	Johnson & Johnson
	 

	 	One Johnson & Johnson Plaza
	 

	 	New Brunswick, N.J. 08933

	9.3	 	Assignment. The rights and obligations in and to this Agreement
shall be binding upon and inure to the benefit of the parties, their legal
representatives, successors and assigns. Neither party may assign this Agreement
without the prior written consent of the other party, except
	 
	 	 	a.) LIFESCAN may freely assign his Agreement in whole or in part to an Affiliate
or to a successor in the entire business to which this Agreement pertains;

19

 

	 	 	b.) UNIVERSAL BIOSENSORS, at the end of the Term, may freely assign the benefit of
this Agreement as part of the sale of the whole or part of its business;
	 
	 	 	c.) LIFESCAN, prior to the end of the Term, shall not unreasonably withhold its
consent to an assignment as part of the sale of the whole or part of UNIVERSAL
BIOSENSORS’ business.

. Any attempted assignment or transfer of such rights or obligations without such consent, except
as provided herein, shall be void and shall automatically terminate all rights of the party
attempting to do so under this Agreement.

     9.4 Integration. It is the mutual desire and intent of LIFESCAN and UNIVERSAL
BIOSENSORS to provide certainty as to their future rights and remedies against each other by
defining the extent of their mutual undertaking as provided herein. Both LIFESCAN and UNIVERSAL
BIOSENSORS acknowledge and agree (a) that no representation or promise not expressly contained in
this Agreement has been made by the other party hereto or by any of its agents, employees,
representatives or attorneys; (b) that such Agreement is not being entered into on the basis if, or
in reliance on, any promise or representation, expressed or implied, covering the subject matter
hereof, other than those which are set forth expressly in this Agreement; and (c) that each party
has had the opportunity to be represented by counsel of its own choice in this matter, including
the negotiations which precede the execution of this Agreement

     9.5 Entire Understanding. This Agreement represents the entire understanding between
UNIVERSAL BIOSENSORS and LIFESCAN with respect to the subject matter in this Agreement, and
supersedes any and all implied or express understandings, agreements or obligations between the
parties with respect thereto whether written or oral.

     9.6 Undertakings by LIFESCAN. LIFESCAN makes no representation or warranty that
LIFESCAN or an Affiliate will market any product resulting from the

20

 

Program or that, if LIFESCAN or an Affiliate does market a product, such product will be the
exclusive means by which LIFESCAN or an Affiliate will participate in the LIFESCAN Field or any
other Field.

     9.7 Force Majeure. Neither party shall be liable for failure to perform as required
by any provisions of this Agreement where such failure results from a cause beyond such party’s
control, such as acts of God, regulation or other acts of civil or military authority, required
approval of government bodies, fires, strikes, floods, epidemics, quarantine restrictions, riot,
delays in transportation and inabilities due to causes beyond such party’s control to obtain
necessary labor, materials, or manufacturing facilities. In the event of any delay attributable
to any of the foregoing causes, the time for performance affected thereby shall be extended for a
period equal to the time lost by reason of such delay.

     9.8 No Waiver. The waiver by either party, whether express or implied, of any
provisions of this Agreement, or of any breach or default of either party, shall not be construed
to be a continuing waiver of such provision, or of any succeeding breach or default, or a waiver of
any other provisions of this Agreement.

     9.9 Inoperability and Reform. In the event that any term or provision of this
Agreement shall be inoperable either by operation of law or otherwise, the remainder of this
Agreement shall remain in full force and effect, and the parties shall negotiate in good faith to
revise the provision in question to accomplish the original intent of the parties.

     9.10 Arbitration. Any controversy or claim arising out of or relating to this
Agreement or the validity, inducement, or breach thereof, shall be settled by arbitration before a
single arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration
Association (“AAA”) then pertaining (available at www.adr.org), except where those rules conflict
with this provision, in which case this provision controls. Any court with jurisdiction shall
enforce this clause and enter judgment on any

21

 

award. The arbitrator shall be an attorney who has at least 15 years of experience with a law firm
or corporate law department of over 25 lawyers or who was a judge of a court of general
jurisdiction. He shall be selected within ten days of commencement of the arbitration from the
AAA’s National Roster of Arbitrators pursuant to agreement or through selection procedures
administered by the AAA. The arbitration shall be held in San Francisco, California and in
rendering the award the arbitrator must apply the substantive law of New York (except where that
law conflicts with this clause), except that the interpretation and enforcement of this arbitration
provision shall be governed by the Federal Arbitration Act. Within 45 days of initiation of
arbitration, the parties shall reach agreement upon and thereafter follow procedures assuring that
the arbitration will be concluded and the award rendered within no more than eight months from
selection of the arbitrator. Failing such agreement, the AAA will design and the parties will
follow procedures that meet such a time schedule. Each party has the right before or, if the
arbitrator cannot hear the matter within an acceptable period, during the arbitration to seek and
obtain from the appropriate court provisional remedies such as attachment, preliminary injunction,
replevin, etc., to avoid irreparable harm, maintain the status quo or preserve the subject matter
of the arbitration. THE ARBITRATOR SHALL NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR
CONSEQUENTIAL DAMAGES, AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO SEEK SUCH DAMAGES. NO
PARTY MAY SEEK OR OBTAIN PREJUDGMENT INTEREST OR ATTORNEYS’ FEES OR COSTS.

     9.11 Restriction of Distribution of This Agreements. This Agreement shall not be
distributed to persons other than those personnel or LIFESCAN, Affiliates, and UNIVERSAL BIOSENSORS
who have a need to know its contents and those whose knowledge of its contents will facilitate
performance of the obligations of the parties under the Agreement, other than as may be required in
medical emergency, or by statute, law, regulation or judicial order.

22

 

	9.12	 	Choice of Law. The interpretation, validity, and performance of this Agreement
shall be governed by the laws of the State of New York, except for such laws directing
application of the laws of another jurisdiction.

     9.13 No Publicity. Neither party will originate any publicity, news release, or other
public announcement, written or oral, whether to the public press, to stockholders, or otherwise,
relating to this Agreement, to any amendment hereto or to performance hereunder or the existence of
an arrangement between the parties, without the prior written approval of the other party except as
required by statute, law. Regulation, or judicial order. However, if such disclosure is required
by statute, law, regulation or judicial order the disclosing party shall give reasonable prior
notice of such disclosure to the other party and give such other party an opportunity to review and
approve the disclosure. Neither party shall use the name of the other party in any promotional
materials or advertising without the prior express written permission of such other party.

     IN WITNESS WHEREOF, LIFESCAN and UNIVERSAL BIOSENSORS have caused these presents to be signed.

	 	 	 	 	 	 	 
	LIFESCAN, INC.	 	UNIVERSAL BIOSENSORS
	 
	 	 	 	 	 	 
	By:

	 	/a/ Eric P. Milledge	 	By:	 	/s/ Denis Hanley
	 

	 	 
	 	 	 	 
	Name:

	 	Eric P. Milledge	 	Name:	 	Denis Hanley
	 

	 	 
	 	 	 	 
	Title:

	 	Company Group Chairman	 	Title:	 	Director
	 

	 	 
	 	 	 	 

23

 

EXHIBIT A

24

 

EXHIBIT B

	1.	 	Enhancements in performance for a less than 5 second assay, which assay is to be described by
LIFESCAN (the “Assay”), the enhancements to include greater hematocrit performance and
temperature range.
	 
	2.	 	Reduction in Assay volume below 0.5 ml.
	 
	3.	 	Interfacing on an electrochemical sensor moiety to a sample collection moiety to permit
regular, programmed sensing of glucose concentration from a single sampling source.
	 
	4.	 	Reduction of the number of steps required to generate a result through the integration of
various sensor, handling, sample collection, and quality control requirements.
	 
	5	 	Use of second mediators and the like as a means to reduce the quantities of PQQ-GDH enzyme
required for the Assay.
	 
	6.	 	Evaluation of alternate PQQ-GDH enzymes for greater sensitivity and specificity.
	 
	7.	 	Use of technology to measure signals generated from other assay configurations including,
without limitation, immunoassays and competitive binding assays.
	 
	8.	 	Development of other diagnostic tests useful in the LIFESCAN Field.
	 
	9.	 	Development of manufacturing methodology useful in the LIFESCAN Field, but which may also be
useful in UNIVERSAL BIOSENSORS’ Field.

25

 

EXHIBIT C

Australia

Canada

EPO:

France

Germany

Italy

Netherlands

Spain

United Kingdom

Japan

United States

26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]